Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment

Guido Finazzi, MD, Alessandra Iurlo, MD PhD, Bruno Martino, Giuseppe Carli, MD, Attilio Guarini, MD, Richard Noble, MD, Alessandro M. Vannucchi, Nikolas von Bubnoff, MD, Marianna De Muro, MD, Paolo Di Bartolomeo, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Vincenzo Martinelli, MD, Antonio Pezzutto, MD PhD, Vittorio Rosti, MD, Giorgina Specchia, MD, Paolo Bettica, MD PhD, Sara Manzoni, DHSC, BSc, Silvia DI Tollo, DHSC, BSc, Alessandro Rambaldi, MD Prof

Blood (2017) 130 (Supplement 1): 1648.

https://doi.org/10.1182/blood.V130.Suppl_1.1648.1648

Published: 2017

Journal Articles

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Blood (2017) 130 (Supplement 1): 253.

https://doi.org/10.1182/blood.V130.Suppl_1.253.253

Published: 2017

Journal Articles

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Olga Blau, MD PhD, Irina Martynkevich, MD PhD, Franziska Behrenbeck, Claudia D. Baldus, MD, Ekaterina Motiko, Sergei Voloshin, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dorken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2017) 130 (Supplement 1): 5111.

https://doi.org/10.1182/blood.V130.Suppl_1.5111.5111

Published: 2017

Journal Articles

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

Olga Blau, MD PhD, Franziska Behrenbeck, Nikola Suckert, Lars R. Fransecky, MD, Claudia D. Baldus, MD, Renate Arnold, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2016) 128 (22): 2891.

https://doi.org/10.1182/blood.V128.22.2891.2891

Published: 2016

Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD

Blood (2016) 128 (22): 1806.

https://doi.org/10.1182/blood.V128.22.1806.1806

Published: 2016

Journal Articles

Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients

Olga Blau, MD PhD, Rimma Berenstein, Claudia Baldus, MD PhD, Nikola Suckert, Kathrin Rieger, MD, Axel Nogai, MD, Antonio Pezzutto, MD PhD, Bernd Doerken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2015) 126 (23): 4970.

https://doi.org/10.1182/blood.V126.23.4970.4970

Published: 2015

Journal Articles

SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients

Rimma Berenstein, Igor Wolfgang Blau, MD PhD, Axel Nogai, MD, Marlies Waechter, Martin Schmidt-Hieber, MD PhD, Antonio Pezzutto, MD PhD, Bernd Doerken, MD PhD, Olga Blau, MD PhD

Blood (2015) 126 (23): 5325.

https://doi.org/10.1182/blood.V126.23.5325.5325

Published: 2015

Journal Articles

Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML

Anne Flörcken, MD, Schneider Tanja, MD, Anju Singh, MD, Seval Türkmen, MD, Burmeister Thomas, MD PhD, Joannis Anagnostopoulos, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Jörg Westermann, MD PhD

Blood (2014) 124 (21): 1006.

https://doi.org/10.1182/blood.V124.21.1006.1006

Published: 2014

Journal Articles

Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation

Olga Blau, MD PhD, Ekaterina Slonova, Rimma Berenstein, Axel Nogai, MD, Kathrin Rieger, MD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2014) 124 (21): 2576.

https://doi.org/10.1182/blood.V124.21.2576.2576

Published: 2014

Journal Articles

Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells

Rimma Berenstein, Olga Blau, MD PhD, Axel Nogai, MD, Marlies Wächter, Martin Schmidt-Hieber, MD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2014) 124 (21): 3357.

https://doi.org/10.1182/blood.V124.21.3357.3357

Published: 2014

Journal Articles

Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma

Rimma Berenstein, Blau Igor Wolfgang, MD, PhD, Axel Nogai, MD, Marlies Wächter, Antonio Pezzutto, MD, PhD, Bernd Dörken, MD, PhD, Olga Blau, MD, PhD

Blood (2013) 122 (21): 3149.

https://doi.org/10.1182/blood.V122.21.3149.3149

Published: 2013

Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD PhD, Mathias J. Rummel, MD PhD, Antonio Pezzutto, MD PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD PhD, Martin H. Dreyling, MD PhD

Blood (2007) 110 (11): 4501.

https://doi.org/10.1182/blood.V110.11.4501.4501

Published: 2007

Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem Cell Transplantation (ASCT) - A Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD, PhD, Mathias J. Rummel, MD, PhD, Antonio Pezzutto, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD, Martin Dreyling, MD, PhD

Blood (2005) 106 (11): 4786.

https://doi.org/10.1182/blood.V106.11.4786.4786

Published: 2005

NARROW

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients

SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients

Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML

Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation

Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells

Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem Cell Transplantation (ASCT) - A Phase II Trial of the European MCL Network.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only